Answer
Tagrisso (osimertinib mesylate) monotherapy is indicated as adjuvant treatment after complete tumour resection in adults with stage IB–IIIA non-small cell lung cancer whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations.
Sources for this answer
- Tagrisso 40 mg film-coated tabletsAstraZeneca UK Limited · emc · SmPC §4.1 Therapeutic Indications · Version 32Document updated
Sources checked